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Summary
Antiviral drug resistance hepatitis B virus (HBV) variants (HBV- DR) occur spontane-
ously in chronic hepatitis B (CHB) patients and after exposure to nucleos(t)ide ana-
logues (NUCs). We determined the prevalence of HBV- DR variants among participants 
of the Hepatitis B Research Network (HBRN) Cohort Study conducted at 21 sites in the 
United States (US) and Canada. Samples obtained from 1342 CHB participants aged 
≥18 years, and who were currently not receiving NUCs, were tested for HBV- DR vari-
ants by Sanger sequencing. In addition, next generation sequencing (NGS) was used to 
characterize HBV- DR variants from 66 participants with and 66 participants with no 
prior NUC exposure matched for HBV genotype and HBV DNA level. Half the partici-
pants were men, 75% Asian, 26% HBeAg positive. Primary HBV- DR variants were de-
tected by Sanger sequencing in 16 (1.2%) participants: 2/142 (1.4%) with and 14/1200 
(1.2%) without prior NUC exposure; only 1 of these 16 had a secondary variant. In total, 
23 (1.7%) participants had secondary variants, including 1 with prior NUC experience. 
In the subset of 132 participants, NGS detected HBV- DR variants in a higher proportion 
of participants: primary variants in 18 (13.6%) (8 [12.1%] with, and 10 [15.2%] without 
prior NUC therapy) and secondary variants in 10 (7.6%) participants. Based on Sanger 
sequencing, prevalence of primary HBV- DR variants is low (1.2%) among adults with 
CHB in US/Canada. The similar low prevalence of HBV- DR variants in participants with 
and without NUC treatment suggests transmission of these variants is uncommon.
K E Y W O R D S
antiviral treatment, hepatitis B virus, next generation sequencing, nucleos(t)ide analogues, 
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1  | INTRODUCTION
Chronic hepatitis B virus (HBV) infection remains a major global health 
problem with most African countries and many Asian countries still 
classified as highly endemic areas.1 Treatment options for chronic HBV 
infection include either peginterferon alfa administered for a finite 
duration or nucleos(t)ide analogues (NUCs) administered for several 
years and often for life. A disadvantage of long- term NUC administra-
tion is the selection for HBV variants that confer resistance to these 
drugs. These variants are termed primary drug resistance (DR) variants 
and are more commonly associated with NUCs that have a low genetic 
barrier to drug resistance such as lamivudine, adefovir and telbivudine 
than NUCs with a high barrier to drug resistance such as entecavir 
and tenofovir. HBV- DR variants are selected during NUC treatment 
because they can overcome suppression by the NUC used but they 
generally have less replication fitness.2,3 However, additional muta-
tions that restore replication fitness may be selected during long- term 
treatment with NUCs.4 These mutations are called secondary or com-
pensatory HBV- DR variants.
Selection of primary HBV- DR variants can lead to virological and 
biochemical breakthrough, hepatitis flares, hepatic decompensation 
and even death.
While most HBV- DR variants are selected during NUC therapy, 
they can also be present in patients with chronic HBV infection who 
have never been treated with NUCs because HBV replicates through 
an error prone reverse transcription of pregenomic RNA to HBV DNA. 
This is further compounded by very high rates of HBV replication of 
up to 1012 virions per day in some patients. It has also been suggested 
that HBV- DR variants may be transmitted from patients receiving 
NUCs to HBV- susceptible persons.5 This is of most concern in coun-
tries where NUCs with low barrier to resistance are frequently used 
as first- line therapy. A meta- analysis of 106 studies examining the 
prevalence of HBV- DR variants in 12 212 persons with chronic HBV 
infection who had never received NUCs found an overall prevalence 
of 5.73% (95% confidence interval [CI]: 4.85%- 6.61%); however, there 
were wide geographical variations ranging from 20% in Africa to 0% in 
Brazil.6 An important reason for the wide range in results is differences 
in sensitivities of assays used to detect DR variants. Sensitivities of as-
says used in these studies range from Sanger or population sequencing 
which can only detect variants present in ≥20% of the virus pool, line 
probe (reverse hybridization assay) or mass spectrometry which can 
detect variants present in roughly 5% of the virus pool, to next gener-
ation sequencing (NGS) which can detect variants present in <1% of 
the virus pool.3,7
The finding of HBV- DR variants, particularly primary variants, 
in patients with chronic HBV infection who have not been treated 
with NUCs has important epidemiologic and clinical implications. 
Epidemiologically, the identification of primary variants in NUC- naïve 
patients would confirm that transmission of these less fit variants can 
result in chronic infection in susceptible persons. Clinically, this find-
ing indicates that infected patients would be less likely to respond to 
NUCs that are ineffective against these variants. We took advantage 
of the large cohort of participants with chronic HBV infection in the 
Hepatitis B Research Network (HBRN) to 1 determine the prevalence 
of primary and secondary HBV- DR variants in North American adults 
with chronic HBV infection not receiving NUC using Sanger sequenc-
ing, 2 describe the prevalence of HBV- DR variants according to socio-
demographic and clinical characteristics, and 3 compare the findings 
of Sanger sequencing with NGS in the detection of these variants in a 
subset of HBRN participants.
2  | METHODS
2.1 | Study population
The HBRN is a cooperative network of investigators funded by the 
National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK), National Institutes of Health (NIH). The Adult Cohort Study 
conducted in 21 clinical centres across the United States (US) and 
in Toronto, Canada, enrolled hepatitis B surface antigen (HBsAg)- 
positive adults who were 18 years or older without evidence of he-
patic decompensation, hepatocellular carcinoma, liver transplant or 
human immunodeficiency virus infection and were not receiving an-
tiviral therapy. Participants who met clinical indications for treatment 
after enrolment into the HBRN Cohort Study received treatment 
through HBRN clinical trials or standard of care per site investigator. 
Details of the HBRN Cohort Study protocol and characteristics of the 
adult participants had been previously described.8 Institutional review 
board or ethics committee approval was obtained from all clinical sites 
and all participants provided written informed consent.
2.1.1 | NGS subpopulation
To compare the detection rate of HBV- DR variants by Sanger se-
quencing vs NGS, samples from participants who had prior exposure 
to NUCs for ≥90 days and had available results for HBV- DR variants 
by Sanger sequencing, and samples from an equal number of partici-
pants with no prior exposure to NUC matched for HBV genotype and 
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HBV DNA level, were selected for testing of HBV- DR variants by 
NGS. Selection of samples for NGS occurred in April 2015 while data 
for Sanger sequencing continued to accrue until July 2016.
2.2 | Data and sample collection
History of prior HBV antiviral therapy including names of medications, 
and start and stop dates were based on self- reporting by participants 
and systematically collected. Research blood samples were collected 
at each visit and sent to the NIDDK central repository where they 
were stored at −80°C. Research samples collected at the baseline visit 
were used for HBV- DR variant testing; however, when samples were 
not available at the baseline visit, samples obtained at or prior to the 
week 24 follow- up visit were used. Clinical laboratory results closest 
to the research sample collection date were analysed, provided that 
the results were obtained >90 days from any NUC exposure.
2.3 | Definition of HBV- DR variants
To focus on variants that have been confirmed to be associated with 
resistance to HBV NUCs and to avoid the inclusion of polymorphic 
variants, we reviewed the published literature and defined a priori 
a list of primary (A181T/V, T184A/C/F/G/I/L/M/S, S202C/G/I, 
M204I/V, N236T, M250I/L/V) and secondary (L80I/V, I169T, V173L, 
L180M) HBV- DR variants for analysis in this study.
2.4 | Laboratory testing
2.4.1 | 2.4.1 HBV DNA
HBV DNA levels were tested at a Central Virology Laboratory 
(University of Washington, Seattle, WA, USA) using a real- time 
polymerase chain reaction (PCR) assay (COBAS Ampliprep/COBAS 
TaqMan HBV Test, v.2.0; Roche Molecular Diagnostics, Branchburg, 
NJ, USA), which has a lower limit of detection of 20 IU/mL, and sup-
plemented with local results when research samples were not avail-
able for central testing.
2.4.2 | HBV Genotype
HBV genotyping was determined at the Molecular Epidemiology 
and Bioinformatics Laboratory in the Division of Viral Hepatitis at 
the Centers for Disease Control and Prevention (CDC) with mass 
spectrometry.9
2.4.3 | HBV- DR variant
HBV- DR variant testing was performed at the same CDC laboratory. 
The sequences of the HBV polymerase spanning nucleotide positions 
311- 1021 were determined by Sanger sequencing. Variants were 
reported if they comprised more than 25% of the viral population, 
based on the height of a secondary chromatogram peak of the con-
sensus sequence. Next generation sequencing was performed on 
MiSeq Illumina platform using the v3 (600) chemistry (Illumina, San 
Diego, CA, USA) that provides paired reads with 301 nucleotides in 
each direction. The covered region corresponded to nucleotide posi-
tions 1225- 1935 of the HBV polymerase gene or from amino acid 
61 to 257 of the RT domain. To prepare the libraries for each partici-
pant, a shorter nested PCR fragment was obtained and tagged with 
the larger external fragment to ensure complete coverage. The indi-
vidual samples were barcoded with six specific 10- mer sequences on 
each end. The barcoded amplicons were indexed for multiplexing with 
21 different 6- mer barcodes. Next generation sequencing data were 
demultiplexed by MiSeq by indexes and then by barcodes on CLC 
Genomics Workbench v7.5.1. (QIAGEN, Aarhus A/S, www.clcbio.
com). Sequence reads with correct barcodes were mapped to refer-
ence coding HBV polymerase sequences from the appropriate geno-
type and analysed for low frequency variants with a cut- off at ≥1%, 
where the frequency is calculated based on the coverage per site. The 
data for the mutation sites of interest were extracted and compared 
to the data from Sanger sequencing.
2.5 | Statistical analyses
Summary statistics were presented for the overall sample. 
Demographic, clinical and virological characteristics were described 
using frequency and percent for categorical variables and median (in-
terquartile range) for continuous variables. The frequency and percent 
of primary DR variants was given for the overall sample; according to 
demographic, clinical and virological characteristics; and according to 
past NUC exposure. Summary statistics were also presented for the 
NGS subset (overall and by prior NUC use). To compare the distribution 
of continuous variables between those with and without prior NUC 
use, Kruskal- Wallis nonparametric tests were performed. Pearson’s 
chi- square tests were used for categorical variables. Statistical signifi-
cance was determined as P<.05. For the subpopulation with at least 
one DR variant (based on either Sanger or NGS results), we provided 
individual- level listings to show prior NUC use, HBV genotype, HBV 
DNA level and both Sanger and NGS results. SAS 9.3 (SAS Institute, 
Cary NC, USA) was used for statistical analyses.
3  | RESULTS
3.1 | Characteristics of the study population
As of 5 July 2016, 1993 participants were enrolled into the HBRN 
Cohort Study. For this analysis, 430 participants were excluded be-
cause they were found to be either HBsAg negative at enrolment or 
belonged to groups that were specifically targeted for enrolment (par-
ticipants with acute hepatitis B, flares of chronic hepatitis B (CHB), 
or hepatitis D coinfection; participants who were pregnant, or were 
potential candidates for HBRN clinical trials or immunology study).8 
Figure 1 shows a flow diagram of participant selection. Of 1563 
potentially eligible participants, an additional 221 participants were 
excluded because DR variant testing from research blood samples col-
lected at or before the week 24 visit was not available, HBV DNA 
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level was too low for HBV- DR testing, antiviral therapy was stopped 
less than 90 days prior to research sample collection or dates of HBV 
antiviral therapy were unknown.
In total, 1342 participants were included in the analysis of prev-
alence of and risk factors associated with HBV- DR variants based 
on Sanger sequencing. All 1342 participants included were enrolled 
prior to switching from “consecutive” to “targeted” enrolment, and all 
samples used in this study were collected between 2011 and 2014. 
Median age of the participants studied was 42 years, and 51% were 
men. A majority of the participants were Asian (75%), born outside the 
USA or Canada (82%). Approximately one- quarter (26%) were hepati-
tis B e antigen (HBeAg) positive, median HBV DNA level was 4.0 log10 
IU/mL, and one- third had alanine aminotransferase (ALT) level within 
normal range (≤30 U/L for men and ≤20 U/L for women). The predom-
inant HBV genotypes were B (39%) and C (33%) followed by A (18%) 
and D (7%) (Table 1).
One hundred and forty- two (10.6%) participants had received 
NUCs previously ranging in duration from 0.5 to 144 months (median 
19.2). The total duration of NUC treatment was <1 year in 41%, 
1- 3 years in 36%, and >3 years in 23% of treated participants. All 142 
participants treated with NUCs had stopped treatment ≥90 days prior 
to DR variant testing with the vast majority (91.4%) having stopped 
NUCs >6 months before testing. The most common prior NUC was 
lamivudine (n=67), with similar numbers having previously received 
adefovir (23), entecavir (28), or tenofovir (20) and very few having re-
ceived telbivudin (Table 2).
3.2 | Prevalence of primary and secondary HBV- DR 
variants based on Sanger sequencing
Sixteen (1.2%) participants had primary HBV- DR variants based 
on Sanger sequencing including 2/142 (1.4%) with prior NUC and 
14/1200 (1.2%) with no prior NUC therapy. Both participants with 
prior NUC had the A181T/V variant detected (1 prior adefovir and 
1 prior tenofovir). Among the 14 participants with no prior NUC 
therapy, 3 had A181T/V, 2 S202C/G/I, 4 M204I/V, and 5 M250I/L/V 
F IGURE  1 Flow diagram of participant selection. Among 1993 participants enrolled, 11 were excluded because they were found to be 
HBsAg negative at enrolment based on testing at the central laboratory and 419 were excluded because they had acute HBV or HDV infection 
or belong to special groups enrolled after the protocol was switched from “consecutive” to “targeted” enrolment. Of the 1563 potentially eligible 
participants, 198 were excluded because samples within the first 24 weeks of enrolment were not available or HBV- DR resistance data were 
not available (mostly due to low viremia precluding sequencing). An additional 23 participants were excluded because research samples were 
collected after the participants started treatment or within 90 days of stopping treatment or dates of HBV treatment were unknown. Thus, 1342 
participants were included in the analysis.
Drug Resistance Data 
Not Available
N = 198
Treatment-Related Exclusions
N = 23
HBsAg(+) 
N = 1982
General Exclusions
N = 419
Acute
N = 58
Targeted groups
N = 341
HDV
N = 66
Potentially Eligible
N = 1563
Sample Collected after 
Week 24
N = 52
On Treatment or Stopped Treatment 
< 90 days prior to Sample Collection
N = 22
Unknown dates of HBV Treatment
N = 1
N = 1365
*At baseline visit
Data Not Available^
N = 137
Analytic Sample 
Prevalence Estimates
N = 1342
Miscellaneous 
N = 9
HBRN Cohort
N = 1993 HBsAg(–) Central Lab Results*
N = 11
^Includes samples with low or 
undetectable HBV DNA
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(Table 2). Only one of the 16 participants with primary HBV- DR vari-
ants had a secondary DR variant detected by Sanger sequencing. The 
proportion of participants with primary HBV- DR variants in each cat-
egory of demographic and clinical characteristics was similar (Table 1).
Twenty- three (1.7%) participants had secondary HBV- DR variants 
including 1 (0.7%) with prior NUC and 22 (1.8%) with no prior NUC 
therapy. The participant with prior NUC received telbivudine and 
had L80I/V variant detected, but no primary DR variants detected by 
Sanger sequencing. The L80I/V variant was also the most common 
secondary DR variant (20/22) detected among those with no prior 
NUC (Table 2).
In total, 38 (2.8%) participants had either primary or secondary 
HBV- DR variants detected by Sanger sequencing. The prevalence of 
TABLE  1 Frequency of primary HBV- DR variants (based on 
Sanger Sequencing) by participant characteristics
Characteristic All (Column %)
Primary HBV- DR Variant 
(Row %)
Present Absent
N 1342 16 (1.2) 1326 (98.8)
Age (y) N=1342
Median (IQR) 41.9 (33.2, 51.7)
18—<40 592 (44.1) 6 (1.0) 586 (99.0)
40—<60 612 (45.6) 6 (1.0) 606 (99.0)
≥60 138 (10.3) 4 (2.9) 134 (97.1)
Sex N=1342
Male 688 (51.3) 8 (1.2) 680 (98.8)
Race N=1339
White 135 (10.1) 2 (1.5) 133 (98.5)
Black 168 (12.5) 0 (0.0) 168 (100.0)
Asian 1000 (74.7) 13 (1.3) 987 (98.7)
Other 36 (2.7) 1 (2.8) 35 (97.2)
Place of Birth N=1338
US or Canada 235 (17.6) 0 (0.0) 235 (100.0)
South America 
or other North 
America
20 (1.5) 1 (5.0) 19 (95.0)
Europe 37 (2.8) 1 (2.7) 36 (97.3)
Asia or Australia 927 (69.3) 14 (1.5) 913 (98.5)
Africa 119 (8.9) 0 (0.0) 119 (100.0)
Presumed Source 
of hepatitis B 
virus (HBV)
N=1342
Vertical 
Transmission
638 (47.5) 4 (0.6) 634 (99.4)
Horizontal 
Transmission
388 (28.9) 4 (1.0) 384 (99.0)
Unknown 316 (23.5) 8 (2.5) 308 (97.5)
Hepatitis B e 
antigen
N=1301
Negative 957 (73.6) 10 (1.0) 947 (99.0)
Positive 344 (26.4) 6 (1.7) 338 (98.3)
HBV DNA (log10 
IU/mL)
N=1311
Median (IQR) 4.0 (3.0, 6.1)
<103 367 (28.0) 4 (1.1) 363 (98.9)
103—<104 316 (24.1) 6 (1.9) 310 (98.1)
104—<107 366 (27.9) 2 (0.5) 364 (99.5)
≥107 262 (20.0) 4 (1.5) 258 (98.5)
Alanine ami-
notransferase x 
ULN
N=1290
Median (IQR) 1.30 (0.93, 2.00)
≤1 ULN 407 (31.6) 2 (0.5) 405 (99.5)
(Continues)
Characteristic All (Column %)
Primary HBV- DR Variant 
(Row %)
Present Absent
>1—<2 ULN 557 (43.2) 12 (2.2) 545 (97.8)
≥2 ULN 326 (25.3) 2 (0.6) 324 (99.4)
HBV Genotype N=1309
A 240 (18.3) 3 (1.3) 237 (98.8)
B 511 (39.0) 6 (1.2) 505 (98.8)
C 427 (32.6) 7 (1.6) 420 (98.4)
D 95 (7.3) 0 (0.0) 95 (100.0)
E/F/G/H/
multiple
36 (2.8) 0 (0.0) 36 (100.0)
Prior Treatment 
with nucleos(t)ide 
analogues (NUC)
N=1342
Yes 142 (10.6) 2 (1.4) 140 (98.6)
Months of prior 
NUC 
Treatmenta
N=140
Median (IQR) 19.2 (10.0, 34.2) 30.5 (1, 
60)
19.2 
(10.0,33.5)
<1 y 58 (41.4) 1 (1.7) 57 (98.3)
1 to 3 y 50 (35.7) 0 (0.0) 50 (100.0)
>3 y 32 (22.9) 1 (3.1) 31 (96.9)
Time since 
stopping HBV 
NUC Treatment
N=142
Median (IQR) 
months
42.6 (15.5, 73.3) 18.1 
(14.0, 
22.2)
43.0 (15.6, 
73.7)
<1 y 26 (18.3) 0 (0.0) 26 (100.0)
1 to 3 y 37 (26.1) 2 (5.4) 35 (94.6)
>3 y 79 (55.6) 0 (0.0) 79 (100.0)
ULN, upper limit of normal.
Number of nonmissing variables is shown for each variable. N (%) for each 
level of categorical variables is shown. For continuous variables, median 
(25th percentile, 75th percentile) are presented.
aStart date of NUC treatment unknown for two participants.
TABLE  1  (Continued)
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primary and secondary HBV- DR variants detected by Sanger sequenc-
ing by prior NUC therapy is shown in Figure 2.
3.3 | Prevalence of primary and secondary HBV- DR 
variants based on NGS
One hundred and ten participants with >90 days prior NUC exposure 
and available Sanger sequencing data and 110 participants with no prior 
NUC exposure matched for HBV genotype and baseline HBV DNA level 
were selected for NGS. Next generation sequencing data were obtained 
for 132/220 (60%) participants: 66 with and 66 without prior NUC. Next 
generation sequencing data were not available for the other 88 partici-
pants, 44 in each group, due to insufficient sample or inadequate coverage 
of the region of interest. There were no differences in demographics, HBV 
genotype, HBV DNA level, ALT level and interval between stopping NUC 
and sample collection (in those who had prior NUC therapy) between the 
132 participants with and 88 without NGS data (data not shown).
Characteristics of the 66 participants with and 66 participants 
without prior NUC exposure with NGS data were similar except that 
the group with prior NUC was more likely to be Asian (P<.01) and 
to be younger (P<.01) (Table 3). Among these 132 participants, NGS 
detected primary HBV- DR variants in 18 (13.6%) participants: eight 
(12.1%) with and 10 (15.2%) without prior NUC therapy. In contrast, 
Sanger sequencing detected primary HBV- DR variants in four (3.0%) 
participants: one (1.5%) with and three (4.5%) without prior NUC 
therapy. When detected using both methods, the primary HBV- DR 
variants detected by Sanger sequencing and NGS were concordant in 
three and discrepant in one participant (#19) where NGS revealed an 
A181F variant that has not been confirmed to be associated with resis-
tance to HBV NUC, while Sanger showed an A181V variant (Table 4).
Next generation sequencing confirmed the presence of secondary 
HBV- DR variants detected by Sanger sequencing in three participants 
and detected secondary HBV- DR variants in seven additional partic-
ipants, making a total of 10 (7.6%): six (9.1%) with and four (6.1%) 
without prior NUC therapy (Tables 3 and 4). The secondary HBV- DR 
variants detected by Sanger sequencing and NGS were concordant 
in all three participants. Only one (#26) of the 10 participants with 
secondary HBV- DR variants was also found to have primary HBV- DR 
variant—M204V detected by NGS but not by Sanger sequencing.
Among the primary HBV- DR variants detected by NGS but not by 
Sanger sequencing, T184A/S was the most common variant observed, 
while V173L and L180M were the most common secondary HBV- DR 
variants detected by NGS but not by Sanger sequencing (Table 4).
In total, 28 of 132 (21%) participants had either primary or second-
ary HBV- DR variants detected by NGS. Of these, eight (#3, 4, 5, 7, 8, 10, 
14 and 23) received NUC therapy after sample collection for HBV- DR 
variant testing. All eight received tenofovir, as monotherapy in six and 
in combination with emtricitabine in the other two participants. Median 
HBV DNA at the start of NUC treatment was 5 log10 IU/mL. HBV 
DNA decreased to levels below quantification in seven, with no break-
through throughout the course of treatment (range 6.1- 58.6 months); 
TABLE  2 Prevalence of primary and secondary HBV- DR variants based on Sanger sequencing, by Prior nucleos(t)ide analogues (NUC) 
Treatment (N=1342)
Prior NUC 
Treatment Type of Prior NUC Treatment
No Yes Adefovir Tenofovir Telbivudine Lamivudine Entecavir Emtricitabine Unknown
No. of participants 1200 142 23 20 5 67 28 1 22
Primary DR variant 
Present, n (%)
14 (1.2) 2 (1.4) 1 (4.3) 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
A181T/V 3 (0.3) 2 (1.4) 1 1
S202C/G/I 2 (0.2) 0 (0.0) 0 0
M204I/V 4 (0.3) 0 (0.0) 0 0
M250I/L/V 5 (0.4) 0 (0.0) 0 0
Secondary DR variant 
present, n (%)
22 (1.8) 1 (0.7) 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Multiple  
(V173L & L180M)
1 (0.1) 0 (0.0) 0
V173L 1 (0.1) 0 (0.0) 0
L80IV 20 (1.7) 1 (0.7) 1
Data presented as number and per cent (column per cent).
F IGURE  2 Prevalence of primary and secondary HBV- DR variants 
in relation to prior nucleos(t)ide analogues therapy
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the remaining patient had decrease in HBV DNA from 6.3 to 1.4 log10 
IU/mL after 6 months of treatment and was lost to follow- up.
4  | DISCUSSION
In this study of 1342 persons with chronic HBV infection living in 
the US and Canada, who were not receiving HBV NUC therapy 
>90 days before enrolment in the HBRN Cohort Study, we found 
a low prevalence of both primary and secondary HBV- DR variants 
using Sanger sequencing, 1.2% and 1.7%, respectively, and 2.8% over-
all. Participants with and without a prior history of NUC therapy had 
similar rates of primary HBV- DR variants, 1.4% vs 1.2%, respectively. 
As expected, the more sensitive assay (NGS) detected a higher rate of 
primary (13.6%) and secondary (7.6%) HBV- DR variants (21% overall), 
with no difference between participants with and those without prior 
Characteristics
ALL Prior NUC No NUC
N=132 N=66 N=66
Age (y) 39.5 (32.8, 48.3) 37.3 (30.9, 44.1) 42.0 (33.6, 52.5)
Male 49.2 54.5 43.9
Race
White 4.6 4.5 4.6
Black 8.4 1.5 15.4
Asian 83.2 92.4 73.8
Other 3.8 1.5 6.2
Place of birth
US and Canada 13.6 9.1 18.2
South America and 
Other North America
3.0 0.0 6.1
Europe 0.8 1.5 0.0
Asia and Australia 77.3 87.9 66.7
Africa 5.3 1.5 9.1
Presumed source of hepatitis B virus (HBV)
Vertical transmission 56.8 60.6 53.0
Horizontal Transmission 21.2 24.2 18.2
Unknown 22.0 15.2% 28.8
Hepatitis B e antigen 
Positive
25.8 28.6 23.1
HBV DNA (log10 IU/mL) 4.0 (3.0, 6.0) 4.5 (3.1, 6.3) 3.5 (2.8, 5.4)
Alanine aminotransferase 
x ULN (U/L)
1.4 (1.0, 2.1) 1.5 (1.0, 2.1) 1.35 (1.0, 2.0)
HBV Genotype
A 13.1 10.8 15.4
B 36.9 40.0 33.8
C 44.6 44.6 44.6
D 4.6 4.6 4.6
Other 0.8 0.0 1.5
Primary DR Variant
Sanger, n (%) 4 (3.0) 1 (1.5) 3 (4.5)
NGS, n (%) 18 (13.6) 8 (12.1) 10 (15.2)
Secondary DR Variant
Sanger, n (%) 3 (2.3) 2 (3.0) 1 (1.5)
NGS, n (%) 10 (7.6) 6 (9.1) 4 (6.1)
ULN, upper limit of normal.
Unless otherwise noted, % is shown for categorical variables. Median (25th percentile, 75th percentile) 
is presented for continuous variables.
All P values >.05.
TABLE  3 Characteristics of participants 
with and without prior nucleos(t)ide 
analogues (NUC) therapy in subset of 
participants with next generation 
sequencing (NGS)
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NUC therapy. The variants detected by Sanger sequencing and NGS 
were concordant except in one participant who had A181V by Sanger 
sequencing but A181F by NGS.
A systematic review and meta- analysis of the prevalence of 
HBV- DR variants from 106 studies involving 12 212 patients with 
chronic HBV infection who had not received prior NUC therapy found 
that the global prevalence of all mutations (primary and secondary) 
was 5.7%, 5.4% for primary and 2.9% for secondary HBV- DR vari-
ants.6 There was significant geographical variation with the highest 
prevalence in China where the pooled prevalence rate of primary 
and secondary DR variants based on >8000 patients was 8% (95% 
CI 6.63- 9.38) while the pooled prevalence rate in other countries was 
1.9% (95% CI 1.06- 2.69). Much of the observed variability could be 
attributed to small number of patients or bias in selection of patients 
studied, uncertainty about prior exposure to NUCs, differences in 
sensitivities of the methods used for detection of HBV- DR variants, 
and differences in definitions of HBV- DR variants with some studies 
focusing on primary DR variants only while others including both pri-
mary and secondary DR variants, and yet others including polymerase 
gene variants of unclear significance. Globally, M204I/V was the most 
common primary HBV- DR variant detected with a pooled prevalence 
of 4.9%, likely due to long- standing use of lamivudine as first- line 
therapy in many countries, particularly China. In our study, M250I/L/V 
was the most common primary HBV- DR variant detected by Sanger 
sequencing and A181T/V and T184A/I/S were the most common pri-
mary HBV- DR variants in the subgroup with NGS data. The difference 
between results of our study and the meta- analysis is likely related 
to the early adoption of entecavir and tenofovir as first- line therapy 
in North America. Furthermore, among participants previously treated 
with lamivudine or adefovir, the interval between stopping these NUCs 
and DR variant testing was long—median 59 (range 3- 165) months.
In our study, 69.3% of the participants were born in Asia and 8.9% 
in Africa, and likely acquired HBV infection in their home countries. 
Despite this, the prevalence of HBV- DR variants among participants in 
our study who had not received NUC therapy was substantially lower 
than that reported in the studies from Asia and Africa. This may be 
related to the fact that more than half of our participants born out-
side the US and Canada immigrated more than 10 years prior to enrol-
ment into this study, which was before NUCs were in widespread use 
in Asia and Africa. Four other US studies that included 713 persons, 
predominantly Asians who had not received NUC therapy, had a sim-
ilarly low prevalence of HBV- DR variants with a pooled prevalence of 
0.71% (95% CI 0- 1.34) based on Sanger sequencing or reverse hybrid-
ization.6,10-13 These findings support that HBV- DR variants are rarely 
found by Sanger sequencing among untreated persons with chronic 
HBV infection who reside in the US and Canada, and transmission of 
these variants to HBV- susceptible persons is uncommon. It should be 
noted that due to a high error rate during replication of HBV DNA, 
these variants may have emerged spontaneously and may not have 
been acquired at the time of infection. Although we found a higher 
prevalence of HBV- DR variants by NGS, the clinical significance of 
these variants present as a minor species is unclear, and most stud-
ies reported no impact of these minor variants on response to NUC 
therapy.14-16 Of the eight participants with DR variants detected by 
NGS who subsequently started NUC therapy, five had primary DR 
variants detected by NGS but none by Sanger sequencing. All eight 
had rapid virologic responses, and none had virologic breakthrough 
throughout the course of treatment.
HBV- DR variants selected during NUC therapy generally revert 
back to wild- type sequence after withdrawal of NUC therapy, although 
these variants may be archived and can be rapidly selected upon re- 
exposure to the same NUC or other NUCs with cross resistance. In 
our study, we found that the prevalence of HBV- DR variants based on 
Sanger sequencing as well as NGS among participants with prior NUC 
was not higher than those without prior NUC, even though some had 
received NUC for more than 3 years. This may be related to the use of 
entecavir or tenofovir as first- line therapy in recent years, and the fact 
that majority of the treated participants had stopped NUC more than 
6 months before testing. In addition, while NGS is more sensitive than 
Sanger in detecting minor variants, HBV- DR variants may represent 
such a low proportion of the virus pool after withdrawal of NUC that 
NGS may still fail to identify all cases.
Our study had a few limitations. The study population consisted 
of persons followed at tertiary care centres and may not be com-
pletely reflective of the general population with chronic HBV infec-
tion in the USA or Canada. Testing for DR variants with NGS was 
not possible in 40% of the samples, limiting the robustness of our 
conclusion on the prevalence of HBV- DR variants when tested by 
highly sensitive assays. However, the only difference between partic-
ipants with NGS data and those in whom we had a technical failure 
with NGS was a shorter duration of prior NUC in those with NGS 
data, median 18.5 vs 25.1 months. All eight participants with base-
line HBV- DR variants who subsequently received NUC therapy had 
rapid virologic responses with no breakthrough but the number is too 
small for us to ascertain the impact of these variants on response to 
NUC therapy. In clinical trials and in clinical practice, baseline testing 
for HBV- DR variants is not performed prior to initiating NUC ther-
apy, and virological responses to NUC therapy—particularly with the 
newer NUCs entecavir or tenofovir—are achieved in the vast majority 
of patients.
In conclusion, our study of more than 1000 persons with chronic 
HBV infection residing in the US and Canada found a low prevalence 
of primary and secondary HBV- DR variants regardless of prior NUC 
therapy, supporting that these variants were either not present or 
disappear after withdrawal of NUC, and that transmission of these 
variants from patients receiving NUC to HBV- susceptible persons is 
probably rare. We confirmed that more sensitive assays such as NGS 
can detect HBV- DR variants in a higher proportion of persons with 
chronic HBV infection; however, the clinical significance of these 
variants present as minor species is uncertain and these variants may 
have emerged spontaneously. Our results could be related to the al-
most exclusive use of entecavir or tenofovir as first- line NUC therapy 
in North America in recent years and we support the World Health 
Organization recommendation that NUCs with high barriers to resis-
tance should be available and accessible to all persons who need treat-
ment for CHB worldwide.17
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